Your session is about to expire
← Back to Search
Lenvatinib + Pembrolizumab for Salivary Gland Cancer
Study Summary
This trial is testing the effectiveness of two drugs, lenvatinib and pembrolizumab, in treating advanced Adenoid Cystic Carcinoma or other salivary gland cancers that have come back or spread to other parts of the body.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 392 Patients • NCT01321554Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have an immune system disorder or have been on steroids or other immune-weakening medicines recently.I have not received a live vaccine within the last 30 days.I have or had lung inflammation that needed steroids.I do not have any infections requiring treatment through my bloodstream.I haven't had any blood clot issues like a stroke or deep vein thrombosis in the last 6 months.I haven't taken any immune system boosters in the last 4 weeks, but I am on a stable dose of erythropoietin.I am 18 years old or older.My brain metastases are stable and I haven't needed steroids for 14 days.I can swallow pills or have a working G-tube.I am positive for HIV, Hepatitis C, or Hepatitis B.I had cancer other than skin cancer more than 2 years ago and am now cancer-free.My cancer can be measured by scans and has grown despite previous treatments.It's been over 4 weeks since my last cancer treatment and any side effects are mild or gone.I am not pregnant, breastfeeding, or planning to become pregnant soon, and I cannot have children due to surgery or menopause.I haven't needed systemic treatment for an autoimmune disease in the last 2 years, except for thyroid issues, vitiligo, type 1 diabetes, or psoriasis.I have not had serious heart issues like heart failure, unstable angina, heart attack, or dangerous arrhythmias in the last 6 months.I have had an organ or tissue transplant.I have a serious wound, ulcer, or fracture that is not healing and is not caused by cancer.I haven't taken any cancer treatment or experimental drugs in the last 4 weeks.I have not had severe bleeding in the last 4 weeks.I don't have conditions affecting drug absorption in my gut.My urine protein levels are not high.My cancer has worsened or shown new symptoms in the last 6 months.I have not used lenvatinib or any PD-1/PD-L1, anti-PD-L2, CTLA-4, OX-40, or CD137 therapies.I am not on any cancer treatments except for bone treatments or palliative radiation if started before joining the study.I have salivary gland cancer, but it's not adenoid cystic carcinoma.I am on dialysis for kidney failure.My high blood pressure is not controlled, even with medication.I am fully active or able to carry out light work.My cancer has returned or spread and cannot be cured with surgery or other treatments.I have been diagnosed with adenoid cystic carcinoma.I am a male and agree to use contraception and not father children during and up to 120 days after the trial.
- Group 1: recurrent/metastatic non-ACC salivary gland cancers (R/M SGC).
- Group 2: recurrent/metastatic adenoid cystic carcinoma (R/M ACC)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there multiple venues in the US that are engaged with this research?
"Presently, this medical trial is being conducted in 8 separate locations around the country including Miami, Commack and Montvale. To minimize travel requirements for participants, it's highly recommended to select the nearest site if possible."
To what magnitude is the current enrollment for this experiment?
"This medical trial requires 64 volunteers that are eligible for inclusion. Participants may be recruited from various locations, including Baptist Alliance MCI in Miami and Memorial Sloan Kettering Commack (All Protocol Activities) located in New jersey."
Is registration open for this research endeavor?
"Affirmative. According to clinicaltrials.gov, this ongoing medical study was first posted on June 2nd 2020 and most recently updated October 26th 2022. The recruitment process is actively seeking 64 patients at 8 different sites."
Are there any adverse effects associated with Lenvatinib treatments?
"Lenvatinib is deemed to be moderately safe as it has been subjected to a Phase 2 clinical trial, providing some evidence of safety but no data in terms of efficacy. As such, the risk factor was assessed at a score of two."
In what therapeutic circumstances is Lenvatinib typically prescribed?
"Lenvatinib is commonly prescribed to combat malignant neoplasms, however it can also be useful in treating unresectable melanoma, microsatellite instability high and cases of chemotherapy-induced disease progression."
Could you provide an overview of the research projects that have explored Lenvatinib as a therapeutic option?
"Currently, 1032 clinical trials are actively studying Lenvatinib's efficacy. 134 of these research projects have moved into Phase 3 testing. Most tests for this medication are located in Sacramento, California; however there is a total of 37 061 sites running investigations on Lenvatinib worldwide."
Share this study with friends
Copy Link
Messenger